Free Trial

OnKure Therapeutics Q1 2023 Earnings Report

OnKure Therapeutics logo
$4.96 -0.06 (-1.20%)
As of 03/10/2025 04:00 PM Eastern

OnKure Therapeutics EPS Results

Actual EPS
-$6.00
Consensus EPS
-$6.30
Beat/Miss
Beat by +$0.30
One Year Ago EPS
N/A

OnKure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OnKure Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

OnKure Therapeutics Earnings Headlines

OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer
The real reason gold is soaring (and likely to continue)
Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!
See More OnKure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email.

About OnKure Therapeutics

OnKure Therapeutics (NASDAQ:OKUR), Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

View OnKure Therapeutics Profile

More Earnings Resources from MarketBeat